NCT04039880View on ClinicalTrials.gov

Absorption, Metabolism and Excretion of 14C-olorofim in Man

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

July 30, 2019

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions

Invasive Fungal Infections

Interventions

DRUG

Olorofim

single oral dose (120 mg, 3.7 MBq)

Trial Locations (1)

9728

PRA Health Sciences, Groningen

Sponsors

Lead Sponsor

F2G Biotech GmbH

Collaborators (1)

PRA Health Sciences

All Listed Sponsors

collaborator

PRA Health Sciences

INDUSTRY

lead

F2G Biotech GmbH

INDUSTRY